The Life Sciences team advised Orchard Therapeutics (Nasdaq: ORTX) on executing a securities purchase agreement to raise gross proceeds of $150 million resulting from the sale of 24,115,755 shares through a private investment in public equity (PIPE) financing.
Orchard Therapeutics is a global gene therapy leader dedicated to transforming the lives of people affected by rare diseases through the development of innovative, potentially curative gene therapies.
Orchard Therapeutics intends to use the net proceeds from the offering to support its growing commercial capabilities, including the launch of LibmeldyTM in Europe, advance its regulatory and clinical development activities and expand its hematopoietic stem cell (HSC) gene therapy approach into larger indications, as well as for general corporate purposes.
The Goodwin team was led by Michael Bison, Ben Marsh, Catherine Magazu, and Humza Bokhari, with invaluable assistance from Andrew Harrow.
For more details, read the press release and articles in Seeking Alpha and Law360.